New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
13:39 EDTBRKR, PKI, TMOThermo Fisher Q2 results bode well for PerkinElmer, Bruker, says Mizuho
After Thermo Fisher reported Q2 earnings and revenue that beat consensus, Mizuho said all but the Diagnostics segment had results above the firm's expectations and that the company's guidance raise was larger than it first appears after its Cole-Parmer divestiture is accounted for. Mizuho maintains its Buy rating and $150 price target on Thermo Fisher and said its results bode well for PerkinElmer (PKI) and Bruker (BRKR).
News For TMO;PKI;BRKR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
08:34 EDTPKIPerkinElmer selloff a buying opportunity, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier recommends investors buy PerkinElmer following the recent pullback in shares. The stock is down 18% over the last month and is now one of the most attractively valued tools companies, Brokmeier tells investors in a research note. He keeps a Buy rating on the name with a $59 price target.
08:21 EDTPKIPerkinElmer weakness creates buying opportunity, says Cantor
Subscribe for More Information
February 7, 2016
20:36 EDTTMOOn The Fly: Top five weekend stock stories
Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Ford (F) plans to build a new assembly plant in Mexico and expand its existing factory near Mexico City, sharply increasing production capacity in the country as it looks to focus its U.S. efforts on trucks and SUVs, the Wall Street Journal reported. 2. GoPro (GPRO) and Microsoft (MSFT) signed a patent licensing agreement late Friday, lifting shares of the action camera maker in after-hours trading. 3. Media reports indicate Twitter (TWTR) could be rethinking its news feed, potentially ordering posts based on popularity rather than chronological date. 4. Apollo Education (APOL) received a second investigative subpoena from California's attorney general related to the marketing, recruiting, accreditation, and other aspects of its for-profit schools. 5. Celgene (CELG), Gilead (GILD), Thermo Fisher (TMO) and Vantiv (VNTV) were mentioned positively by Barron's this weekend, while Church & Dwight (CHD) was called overvalued and GoPro was identified as a possible takeover target by Under Armour (UA) or Sony (SNE).
13:02 EDTTMOThermo Fisher could rise 25% or more in next year, Barron's says
Subscribe for More Information
February 4, 2016
16:30 EDTPKIPerkinElmer sees FY16 adjusted EPS $2.65-$2.75, consensus $2.82
Subscribe for More Information
16:29 EDTPKIPerkinElmer reports Q4 adjusted EPS 86c, consensus 87c
Reports Q4 revenue $608.1M, consensus $617.52M.
January 29, 2016
08:55 EDTTMOThermo Fisher guidance confusion creates buying opportunity, says Baird
Subscribe for More Information
07:51 EDTTMOThermo Fisher reported very storng results, guidance conservative, says Stifel
Subscribe for More Information
January 28, 2016
08:50 EDTTMOThermo Fisher sees FY16 adjusted EPS $7.80-$7.96, consensus $8.19
Subscribe for More Information
08:44 EDTTMOThermo Fisher says company has best position to address China's challenges
Subscribe for More Information
08:39 EDTTMOThermo Fisher expects to continue to face ForEx challenges in 2016
The company said it will continue to target margin expansion to 24%-26% range by 2017. Also said it will be positively impacted by temporary repeal of medical device tax. Comments taken from Q4 earnings conference call.
08:17 EDTTMOThermo Fisher reports Q4 Life Sciences revenue $1.21B
Reports Q4 Analytical Instruments revenue $925M. Reports Q4 Specialty Diagnostics revenue $865M. Repots Q4 Laboratory Products and Services revenue $1.82B.
06:04 EDTTMOThermo Fisher reports Q4 adjusted EPS $2.12, consensus $2.11
Subscribe for More Information
January 27, 2016
14:34 EDTTMONotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use